Since the inception of the Cell Imaging Core Facility in September of 1999, its mission has been to provide state-of-the-art cell imaging technologies to Cancer Center members. This includes different forms of light and fluroescence microscopes, stereo and confocal microscopy, and a laser microdissection system. Images can be captured with several video and CCD cameras, analyzed and manipulated with several image analysis software programs. In addition, the Core provides analytical cytometry services like immunophenotyping and cell cycle analysis. All scientists have the opportunity for expert consultation prior to and during their experiments and receive continuous technical support by the Core personnel throughout the use of any core equipment. Core technicians evaluate the facility's equipment routinely and engage in frequent technical training in order to maintain and warrant the constantly evolving needs and opportunities in this technical research area. In 2004, 57 different groups led by principal investigators from all programs of the Center, including cancer biology, hematologic malignancies, chemical therapeutics, cancer immunlogy, urologic oncology, Gl cancer, breast cancer, and viral oncology, benefited from these core services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-45
Application #
7726481
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
45
Fiscal Year
2007
Total Cost
$74,394
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Dean, Lorraine T; Gehlert, Sarah; Neuhouser, Marian L et al. (2018) Social factors matter in cancer risk and survivorship. Cancer Causes Control 29:611-618
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663
Boudadi, Karim; Suzman, Daniel L; Anagnostou, Valsamo et al. (2018) Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9:28561-28571
Annesley, Colleen E; Rabik, Cara; Duffield, Amy S et al. (2018) Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. Oncotarget 9:35313-35326
Yuan, Ming; Da Silva, Ana Cristina A L; Arnold, Antje et al. (2018) MicroRNA (miR) 125b regulates cell growth and invasion in pediatric low grade glioma. Sci Rep 8:12506
Jacobs, Michael A; Macura, Katarzyna J; Zaheer, Atif et al. (2018) Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. Acad Radiol 25:1405-1414
Ramos, Juan C; Sparano, Joseph A; Rudek, Michelle A et al. (2018) Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). Clin Lymphoma Myeloma Leuk 18:180-190.e2

Showing the most recent 10 out of 2393 publications